maintain disease registers for selected conditions including asthma, used to define asthma are shown in Appendix S1.
| Other morbidities
Data on 39 common and important comorbidities were extracted as described previously (Appendix 2, Table S1 for details of selection process).
14 Data were extracted on age, sex, smoking status and socio-economic deprivation measured using the Carstairs deprivation score. The Carstairs score is a measure of neighbourhood socio-economic deprivation assigned to individuals based on their postcode of residence and has been widely used in healthcare research. 15 , 16 
| Statistical analysis
The prevalence of each of the 39 different comorbidities was measured in people with and without asthma. Univariate and multivariate logistic regression was used to estimate odds ratios with 
| RESULTS
Of 1 424 378 adults in the data set, 84 505 had active asthma (prevalence=5.9%, 95% CI 5.89-5.97). The characteristics of adults with and without asthma are shown in Table 1 . A larger proportion of adults with asthma were women (58.7% vs 50.4% without), were non-smokers and were living in more deprived areas.
| Comorbidities in adults with asthma
The crude prevalence of comorbidity was significantly greater in people with asthma compared to the general population. The crude prevalence of people with one or more health condition was 62.6%
in adults with asthma compared to only 46.2% in those without asthma ( 
| DISCUSSION
This study investigating the prevalence of comorbidity in adults with asthma using a large nationally representative population showed that comorbidity is the norm in adults with asthma, with 62.6% of people having one or more comorbidity. Of the 39 comorbidities evaluated, 36 (92.3%) occurred more often in people with asthma, including depression, anxiety, coronary heart disease, epilepsy, | 1249 migraine and pain. Hypertension was the most prevalent physical condition identified in both groups, but still had one of the largest APDs in prevalence in adults with asthma, with the others being COPD, depression, pain and dyspepsia. In relative terms, however, the comorbidities most likely to be present in people with asthma compared to the general population were COPD, bronchiectasis, eczema, dyspepsia and chronic sinusitis.
Several studies have previously measured the prevalence of comorbidity in people with asthma. A Canadian claims-based study examined differences in comorbidity according to 14 disease categories reporting a 50% greater relative risk of comorbidity among those with asthma compared to those without. 17 A study from the United States found that 26% of people with asthma had one or more comorbidities whilst 10% had three or more; however, this study only measured five comorbid conditions. 18 Similar findings were observed in a study from Germany examining only eight comorbidities, which reported that 26% of people with asthma had at least one comorbidity and 17% had two or more conditions. 19 A greater proportion of patients in our study had at least one comorbidity, suggesting that these studies may have underestimated the prevalence of comorbidity, in part due to the limited number of comorbidities included for evaluation.
Our study identified comorbidities associated with atopic asthma, such as eczema and chronic sinusitis. However in relative terms, the respiratory comorbidities most strongly associated with asthma were COPD, closely followed by bronchiectasis. Similar findings in terms of respiratory comorbidity were seen in a Canadian study and in a recent meta-analysis of observational studies. 20, 21 This association could in part be explained by asthma-COPD overlap syndrome (ACOS) that may be caused by long-term uncontrolled airway inflammation leading to airway remodelling and fixed airway obstruction, or as a result of COPD developing de novo in people with asthma who smoke. 22 These are both potentially modifiable risk factors to preserve respiratory function and reduce the risk of respiratory comorbidity in later life. With regard to bronchiectasis, people with asthma are at increased risk of lower respiratory tract infections including pneumonia that potentially contribute to the development of bronchiectasis. 17 Whilst the diagnosis of asthma is often clinical, we did not use objective measures such as lung function or CT scanning to differentiate between asthma and COPD or bronchiectasis because these data were not available. Due to the cross-sectional nature of our study, we cannot exclude the possibility of coding errors contributing to the observed associations and of some misclassification between diagnoses. Nevertheless, asthma is a recognized comorbidity in people with bronchiectasis as highlighted by a recent prospective international multi-centre cohort study and ACOS is a well-recognized entity, with chronic diseases being generally well recorded with these types of data. 23 It therefore seems prudent to consider these respiratory comorbidities because they may require different treatment approaches or have differential risks of adverse effects from medication, such as the risk of pneumonia with inhaled corticosteroids. 24 In contrast, the relationship between asthma and other common comorbidities is more complex. The association with reflux disease could result from increased diagnosis from closely related symptoms (such as cough) compounded by the use of medicines including oral steroids. Reflux is potentially an important comorbidity associated with an increased risk of asthma exacerbations due to direct airway contact with gastric acid triggering a vasovagal reflex and bronchospasm. 25 An association with hypertension may also be related to the use of chronic inhaled beta2-agonist stimulants or in part due to increased blood pressure screening during routine consultations for asthma, a feature that may also relate to other comorbidities. 26 The observed association between chronic pain and asthma is less understood with only a limited number of studies having been performed linking pain and asthma. 27 Mental health conditions are particularly important to consider, and our study showed a significant association between asthma and several mental health comorbidities, including anxiety and depression. Although several international studies have shown depression
to be approximately twice as common in people with asthma, less consistent associations have been reported with anxiety. 19, 28, 29 Indeed, previous work on multi-morbidity has shown that the prevalence of mental health conditions rises as the number of comorbid conditions increases, particularly in people from more socio-econom-conditions in UK primary care data being well recorded. 36, 37 The definition included the use of asthma controller medication and was based on that used by the UK Quality and Outcomes Framework, a national pay for performance system which provides payment to GPs to keep registers of asthma patients included. This definition excludes those with a history of asthma in the past who no longer receive treatment, which are included in the non-asthma population.
It was also not possible to measure the prevalence of some other comorbidities including NSAID-exacerbated respiratory disease which occurs in approximately 9%-10% of patients with asthma, and for which selective COX-2 inhibitors may be more appropriate in people requiring NSAIDs for the treatment of certain comorbidities such as pain and arthritis. 38, 39 Finally, further analytical work examining the impact of comorbidities on asthma severity, control and healthcare costs is still required for several comorbidities.
In conclusion, this study highlights the significantly greater prevalence of comorbidity in people with asthma that clinicians should be aware when reviewing people with asthma. Further studies are required to assess the generalizability of evidence in comorbid people with asthma and to evaluate generalist approaches to asthma care.
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